ONWARD Medical Announces Upcoming Webcast for Q3 2024 Highlights
ONWARD Medical N.V. (Euronext: ONWD), a pioneering medical technology company, is gearing up to host an engaging webcast aimed at sharing its notable business highlights for the third quarter of 2024. The company specializes in creating advanced spinal cord stimulation therapies that aim to restore movement, function, and independence for those suffering from spinal cord injuries (SCI).
Details of the Webcast
This informative webcast is scheduled for a date in late November, where CEO Dave Marver and his team will present the company’s achievements over the past quarter and share forward-looking insights. Marver’s discussion will cover the innovative approaches ONWARD has taken toward developing solutions that address movement impairments due to spinal injuries.
How to Join the Webcast
Participants interested in joining the conversation can easily do so via Zoom. For those preferring to call in, a range of options is available across several countries including Belgium, France, Germany, and Switzerland among others, ensuring accessibility for a global audience. Meeting ID will be provided at the time of registration.
Innovations in Spinal Cord Treatments
ONWARD Medical's commitment to rehabilitation and recovery through innovative technology has been evidenced by its contributions to the field. The company has developed well-regarded therapies, such as ARC Therapy, which utilize advanced spinal cord stimulation techniques. This technology has been recognized by the FDA with multiple Breakthrough Device Designations, demonstrating its potential impact on patient care.
ARC Therapy and its Impact
Key studies, including the significant Up-LIFT trial, showcased the remarkable effectiveness of non-invasive ARC-EX Therapy, which greatly enhanced upper limb functionality among participants. The results, published in a leading medical journal, underline the promise of ONWARD’s solutions for restoring capabilities in SCI patients.
Future Directions and Clinical Trials
Looking ahead, ONWARD Medical is actively preparing for regulatory submissions for its products in the U.S. and Europe. Concurrently, clinical studies continue to explore the therapeutic uses of ARC-IM to improve outcomes for individuals suffering from SCI-related complications, including issues related to mobility and blood pressure regulation.
Global Presence and Commitment
With its headquarters based in the Netherlands and branches across Europe and the U.S., ONWARD Medical emphasizes its dedication to partnering with the SCI community. The organization seeks to bridge the gap between research and practical rehabilitation through engaging with leading healthcare professionals and institutions.
Staying Informed
For those keen on keeping up with ONWARD Medical’s developments, visiting their official website offers a wealth of information on their strategies and innovative solutions aimed at enhancing recovery for those with SCI. The company also maintains an active presence on social media platforms, inviting stakeholders to engage with their mission and progress.
Frequently Asked Questions
What is the focus of ONWARD Medical?
ONWARD Medical focuses on developing spinal cord stimulation therapies to restore movement and independence for individuals with spinal cord injuries.
How can I participate in the upcoming webcast?
You can register for the webcast via the registration link provided by ONWARD Medical to secure your spot for insights into Q3 2024 highlights.
What is ARC Therapy?
ARC Therapy is a spinal cord stimulation approach developed by ONWARD Medical to potentially restore movement and improve the quality of life for SCI patients.
When is the webcast scheduled?
The webcast is scheduled for late November, providing a convenient opportunity for participants interested in ONWARD Medical's recent advancements.
How does ONWARD Medical stay connected with the SCI community?
ONWARD Medical actively collaborates with researchers and healthcare providers while engaging in informative communication through their website and social media channels.
